Search company, investor...
Illumina company logo


Founded Year




Total Raised


Market Cap


Stock Price


About Illumina

Illumina works to apply technologies and revolutionary assays to the analysis of genetic variation and function. It offers collaborative interactions, rapid delivery of solutions, and focuses on customers. Illumina's array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. The company was founded in 1998 and is based in San Diego, California.

Headquarters Location

5200 Illumina Way

San Diego, California, 92122,

United States


Missing: Illumina's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Illumina's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Illumina

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Illumina in 4 CB Insights research briefs, most recently on Feb 15, 2022.

Expert Collections containing Illumina

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Illumina is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

114 items


Synthetic Biology

382 items


Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Medical Devices

1,070 items - excludes those without working websites.


Health Monitoring & Diagnostics

778 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Illumina Patents

Illumina has filed 1 patent.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • DNA
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, DNA, Biotechnology, Genetics, Gene expression


Application Date


Grant Date



Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Gene expression



Latest Illumina News

Global Epigenetics Market Analysis & Forecasts Report, 2016-2021, 2021-2026F, 2031F Featuring Major Players - Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, & Active Motif -

Nov 28, 2022

The global epigenetics market is expected to grow from $6.15 billion in 2021 to $7.33 billion in 2022 at a compound annual growth rate (CAGR) of 19.18%. The epigenetics market is expected to grow to $14.79 billion in 2026 at a compound annual growth rate (CAGR) of 19.17%. The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market. The rising prevalence of diseases increases the demand for epigenetics. According to the European Commission's Joint Research Centre from Ispra, the number of new cancer cases in the European Union (EU) and European Free Trade Association (EFTA) countries will rise by 21.4%, from 2.8 million in 2020 to 3.4 million in 2040. North America was the largest region in the epigenetics market in 2021. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epigenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. Furthermore, according to the Centers for Disease Control and Prevention (CDC), approximately 659,000 people in the United States die of heart disease each year. The increasing prevalence of cancer and other diseases requires testing and knowing the modifications that happened in the genes, which will invariably increase the usage and demand of epigenetics. Thus, the growing prevalence of cancer and other diseases drives the epigenetics market in the coming years. Technological advancement is the key trend in the epigenetics market. The key players in the epigenetics sector are focusing on developing various technologically advanced products and services to strengthen their position in the market. For instance, in April 2019, Greenwood Genetic Center, a genetic testing services organization based in the United States, in collaboration with the London Health Sciences Centre (LHSC), launched EpiSign, a new diagnostic test centered on disease-specific epigenetic signatures. The EpiSign test, which is performed on a peripheral blood sample, analyses the genome's DNA methylation patterns to demonstrate a diagnosis or help to resolve variants of uncertain significance (VUS) discovered through DNA testing. In December 2020, Exact Sciences, a US-based molecular diagnostic company, acquired Base Genomics for $140 million. As a result of this acquisition, Exact Sciences aims to create a multi-cancer early detection blood test. This acquisition also aids in the acceleration of clinical and commercial development. Base Genomics is a UK-based epigenetics company working on designing a blood test for minimal residual disease and early-stage cancer. The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. Major players in the epigenetics market are Illumina

Illumina Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Illumina Rank

Illumina Frequently Asked Questions (FAQ)

  • When was Illumina founded?

    Illumina was founded in 1998.

  • Where is Illumina's headquarters?

    Illumina's headquarters is located at 5200 Illumina Way, San Diego.

  • What is Illumina's latest funding round?

    Illumina's latest funding round is PIPE.

  • How much did Illumina raise?

    Illumina raised a total of $36.53M.

  • Who are the investors of Illumina?

    Investors of Illumina include LRG Capital Group, ARCH Venture Partners, CW Group, Tredegar, Venrock and 12 more.

  • Who are Illumina's competitors?

    Competitors of Illumina include Beacon Biomedical, Sequentify, CloudSeq, Lifebit, Sirion Biotech, Singular Genomics, Clear Labs, Empiric Logic, ReadCoor, Alnylam Pharmaceuticals and 32 more.

Compare Illumina to Competitors

Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

DNAnexus Logo

DNAnexus, a multiomics platform, is creating scalable and collaborative data technologies to unlock the potential of DNA-based medicine and biotechnology. The company has created a cloud-based DNA data management and biomedical data analysis platform that provides instant online genomics data centers for researchers and sequencing service providers alike.


SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


Virmatics is a bioinformatics software company developing efficient, and automated tools for biomedical researchers. Their software aims to give researchers the ability to plan experiments and record, store, and analyze data with unparalleled flexibility. Virmatics has been a member of the incubator since Fall 2004.


Employing recent advances in sequencing, ASPE bead array, microarray technology, Q'Array is poised to provide a range of DNA testing, including genetic, chromosomal, biochemical, pharmacogenomics, paternity, and forensic identity testing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.